Genentech profit up, forecast light
NEW YORK (Reuters) - Genentech Inc reported higher fourth-quarter profit on Thursday, but sales of its most closely watched drug, Avastin, and its 2009 earnings forecast were shy of Wall Street expectations and its shares fell nearly 2 percent.<div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/businessNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=xMKzfVAA) <img src="http://feedproxy.google.com/~f/reuters/businessNews?i=5Zogq44T" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=5Zogq44T) <img src="http://feedproxy.google.com/~f/reuters/businessNews?i=XLkxI99H" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=XLkxI99H)
</div><img src="http://feedproxy.google.com/~r/reuters/businessNews/~4/imH2g4eVC2I" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/imH2g4eVC2I/idUSTRE50E7X020090115